BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respir Viruses 2009;3:129-42. [PMID: 19627370 DOI: 10.1111/j.1750-2659.2009.00090.x] [Cited by in F6Publishing: 64] [Reference Citation Analysis]
Number Citing Articles
1 Kumaki Y, Morrey JD, Barnard DL. Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice. Future Virol 2012;7:801-18. [PMID: 23420457 DOI: 10.2217/fvl.12.71] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
2 An L, Liu R, Tang W, Wu JG, Chen X. Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs. Antiviral Res 2014;109:54-63. [PMID: 24971493 DOI: 10.1016/j.antiviral.2014.06.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
3 Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, Vilaplana C, Yeboah-Manu D, Chakaya J, Ippolito G, Azhar E, Hoelscher M, Maeurer M; Host-Directed Therapies Network consortium. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis 2016;16:e47-63. [PMID: 27036359 DOI: 10.1016/S1473-3099(16)00078-5] [Cited by in Crossref: 162] [Cited by in F6Publishing: 107] [Article Influence: 27.0] [Reference Citation Analysis]
4 Leber A, Bassaganya-Riera J, Tubau-Juni N, Zoccoli-Rodriguez V, Lu P, Godfrey V, Kale S, Hontecillas R. Lanthionine Synthetase C-Like 2 Modulates Immune Responses to Influenza Virus Infection. Front Immunol 2017;8:178. [PMID: 28270815 DOI: 10.3389/fimmu.2017.00178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
5 Fedson DS. Influenza Vaccination or Treatment for Influenza-Associated Myocardial Infarction. The Journal of Infectious Diseases 2012;205:1618-9. [DOI: 10.1093/infdis/jis245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Cheng CK, Tsai CH, Shie JJ, Fang JM. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? Future Med Chem 2014;6:757-74. [PMID: 24941871 DOI: 10.4155/fmc.14.30] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
7 Wei F, Gao C, Wang Y. The role of influenza A virus-induced hypercytokinemia. Crit Rev Microbiol 2021;:1-17. [PMID: 34353210 DOI: 10.1080/1040841X.2021.1960482] [Reference Citation Analysis]
8 Reichert T, Chowell G, Nishiura H, Christensen RA, McCullers JA. Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BMC Infect Dis 2010;10:5. [PMID: 20059763 DOI: 10.1186/1471-2334-10-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
9 Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res 2018;150:202-16. [PMID: 29325970 DOI: 10.1016/j.antiviral.2018.01.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
10 Kido H, Indalao IL, Kim H, Kimoto T, Sakai S, Takahashi E. Energy metabolic disorder is a major risk factor in severe influenza virus infection: Proposals for new therapeutic options based on animal model experiments. Respir Investig 2016;54:312-9. [PMID: 27566378 DOI: 10.1016/j.resinv.2016.02.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
11 Bao J, Marathe B, Govorkova EA, Zheng JJ. Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses. Angew Chem 2016;128:3499-502. [DOI: 10.1002/ange.201511361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Brett SJ, Myles P, Lim WS, Enstone JE, Bannister B, Semple MG, Read RC, Taylor BL, McMenamin J, Nicholson KG, Nguyen-Van-Tam JS, Openshaw PJ; Influenza Clinical Information Network (FLU-CIN). Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One 2011;6:e18120. [PMID: 21541017 DOI: 10.1371/journal.pone.0018120] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
13 Zabetakis I, Lordan R, Norton C, Tsoupras A. COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation. Nutrients. 2020;12. [PMID: 32438620 DOI: 10.3390/nu12051466] [Cited by in Crossref: 159] [Cited by in F6Publishing: 145] [Article Influence: 79.5] [Reference Citation Analysis]
14 Hudson J, Vimalanathan S. Echinacea—A Source of Potent Antivirals for Respiratory Virus Infections. Pharmaceuticals 2011;4:1019-31. [DOI: 10.3390/ph4071019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
15 Ison MG. Adjuvant immunosuppression in the management of severe influenza: friend or foe? Crit Care Med. 2014;42:457-459. [PMID: 24434448 DOI: 10.1097/ccm.0b013e3182a63779] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hontecillas R, Roberts PC, Carbo A, Vives C, Horne WT, Genis S, Velayudhan B, Bassaganya-Riera J. Dietary abscisic acid ameliorates influenza-virus-associated disease and pulmonary immunopathology through a PPARγ-dependent mechanism. J Nutr Biochem 2013;24:1019-27. [PMID: 22995385 DOI: 10.1016/j.jnutbio.2012.07.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
17 Wu X, Wu X, Sun Q, Zhang C, Yang S, Li L, Jia Z. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics 2017;7:826-45. [PMID: 28382157 DOI: 10.7150/thno.17071] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
18 Fedson DS. Influenza, evolution, and the next pandemic. Evol Med Public Health 2018;2018:260-9. [PMID: 30455951 DOI: 10.1093/emph/eoy027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
19 Lee CC, Liu Y, Lu KT, Wei C, Su K, Hsu WT, Chen SC. Comparison of influenza hospitalization outcomes among adults, older adults, and octogenarians: a US national population-based study. Clin Microbiol Infect 2021;27:435-42. [PMID: 32325126 DOI: 10.1016/j.cmi.2020.04.013] [Reference Citation Analysis]
20 Oh TK, Song IA, Jeon YT. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea. J Pers Med 2021;11:116. [PMID: 33578937 DOI: 10.3390/jpm11020116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Hudson JB. Applications of the phytomedicine Echinacea purpurea (Purple Coneflower) in infectious diseases. J Biomed Biotechnol. 2012;2012:769896. [PMID: 22131823 DOI: 10.1155/2012/769896] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
22 Walsh EE. Statins and influenza: can we move forward? J Infect Dis 2012;205:1-3. [PMID: 22170953 DOI: 10.1093/infdis/jir693] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
23 Keilich SR, Bartley JM, Haynes L. Diminished immune responses with aging predispose older adults to common and uncommon influenza complications. Cell Immunol 2019;345:103992. [PMID: 31627841 DOI: 10.1016/j.cellimm.2019.103992] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
24 Wong JP, Christopher ME, Viswanathan S, Schnell G, Dai X, Van Loon D, Stephen ER. Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza. Expert Review of Respiratory Medicine 2014;4:171-7. [DOI: 10.1586/ers.10.15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
25 Snell NJC. Pandemic Influenza — Prevention and Treatment: Past, Present and Future. Pharm Med 2010;24:1-6. [DOI: 10.1007/bf03256791] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Shie JJ, Fang JM. Development of effective anti-influenza drugs: congeners and conjugates - a review. J Biomed Sci 2019;26:84. [PMID: 31640786 DOI: 10.1186/s12929-019-0567-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
27 Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol. 2010;23:343-352. [PMID: 20712478 DOI: 10.1089/vim.2010.0016] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
28 Cloutier A, Marois I, Cloutier D, Verreault C, Cantin AM, Richter MV. The prostanoid 15-deoxy-Δ12,14-prostaglandin-j2 reduces lung inflammation and protects mice against lethal influenza infection. J Infect Dis 2012;205:621-30. [PMID: 22219346 DOI: 10.1093/infdis/jir804] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
29 Short KR, Brooks AG, Reading PC, Londrigan SL. The fate of influenza A virus after infection of human macrophages and dendritic cells. J Gen Virol 2012;93:2315-25. [PMID: 22894921 DOI: 10.1099/vir.0.045021-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
30 Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013;99:417-35. [PMID: 23831494 DOI: 10.1016/j.antiviral.2013.06.018] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 10.9] [Reference Citation Analysis]
31 Viasus D, Paño-pardo JR, Pachón J, Riera M, López-medrano F, Payeras A, Fariñas MC, Moreno A, Rodríguez-baño J, Oteo JA, Martínez-montauti J, Torre-cisneros J, Segura F, Gudiol F, Carratalà J. Pneumonia Complicating Pandemic (H1N1) 2009: Risk Factors, Clinical Features, and Outcomes. Medicine 2011;90:328-36. [DOI: 10.1097/md.0b013e31822e67a7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
32 Muthaiyan M, Naorem LD, Seenappa V, Pushan SS, Venkatesan A. Ebolabase: Zaire ebolavirus-human protein interaction database for drug-repurposing. Int J Biol Macromol 2021;182:1384-91. [PMID: 34015403 DOI: 10.1016/j.ijbiomac.2021.04.184] [Reference Citation Analysis]
33 Hui DS, Lee N, Chan PK. Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res 2013;98:410-6. [PMID: 23578727 DOI: 10.1016/j.antiviral.2013.03.019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
34 Bao J, Marathe B, Govorkova EA, Zheng JJ. Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses. Angew Chem Int Ed Engl 2016;55:3438-41. [PMID: 26833677 DOI: 10.1002/anie.201511361] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
35 Fedson DS, Opal SM. The controversy over H5N1 transmissibility research: an opportunity to define a practical response to a global threat. Hum Vaccin Immunother 2013;9:977-86. [PMID: 23391967 DOI: 10.4161/hv.23869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
36 InFACT Global H1N1 Collaboration. InFACT: a global critical care research response to H1N1. Lancet 2010;375:11-3. [PMID: 19906418 DOI: 10.1016/S0140-6736(09)61792-X] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
37 Opal SM. Coming soon to an ICU near you: severe pandemic influenza in ICU patients in Spain. Crit Care 2009;13:196. [PMID: 19863761 DOI: 10.1186/cc8112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Corrales-medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia: A systematic review. Journal of Infection 2011;63:187-99. [DOI: 10.1016/j.jinf.2011.06.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
39 Kido H. Influenza virus pathogenicity regulated by host cellular proteases, cytokines and metabolites, and its therapeutic options. Proc Jpn Acad Ser B Phys Biol Sci 2015;91:351-68. [PMID: 26460316 DOI: 10.2183/pjab.91.351] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
40 Nicholls JM. The battle between influenza and the innate immune response in the human respiratory tract. Infect Chemother 2013;45:11-21. [PMID: 24265946 DOI: 10.3947/ic.2013.45.1.11] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
41 Hui DS, Lee N, Chan PK. Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest 2010;137:916-25. [PMID: 20022969 DOI: 10.1378/chest.09-2344] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
42 Michaelis M, Geiler J, Naczk P, Sithisarn P, Leutz A, Doerr HW, Cinatl J. Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression. PLoS One. 2011;6:e19705. [PMID: 21611183 DOI: 10.1371/journal.pone.0019705] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 7.5] [Reference Citation Analysis]
43 Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med 2010;38:e91-7. [PMID: 19935413 DOI: 10.1097/CCM.0b013e3181c92eeb] [Cited by in Crossref: 142] [Cited by in F6Publishing: 77] [Article Influence: 11.8] [Reference Citation Analysis]
44 Hui DS, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Respir Viruses 2013;7 Suppl 3:52-9. [PMID: 24215382 DOI: 10.1111/irv.12171] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
45 Tang BM, Shojaei M, Teoh S, Meyers A, Ho J, Ball TB, Keynan Y, Pisipati A, Kumar A, Eisen DP, Lai K, Gillett M, Santram R, Geffers R, Schreiber J, Mozhui K, Huang S, Parnell GP, Nalos M, Holubova M, Chew T, Booth D, Kumar A, McLean A, Schughart K. Neutrophils-related host factors associated with severe disease and fatality in patients with influenza infection. Nat Commun 2019;10:3422. [PMID: 31366921 DOI: 10.1038/s41467-019-11249-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 17.3] [Reference Citation Analysis]
46 Maurya A, Khan F, Bawankule DU, Yadav DK, Srivastava SK. QSAR, docking and in vivo studies for immunomodulatory activity of isolated triterpenoids from Eucalyptus tereticornis and Gentiana kurroo. Eur J Pharm Sci. 2012;47:152-161. [PMID: 22659375 DOI: 10.1016/j.ejps.2012.05.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
47 Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs 2010;70:1349-62. [PMID: 20614944 DOI: 10.2165/11537960-000000000-00000] [Cited by in Crossref: 89] [Cited by in F6Publishing: 81] [Article Influence: 7.4] [Reference Citation Analysis]
48 Joshi R, Venkatesan S, Myles PR. A UK general practice population cohort study investigating the association between lipid lowering drugs and 30-day mortality following medically attended acute respiratory illness. PeerJ 2016;4:e1902. [PMID: 27114868 DOI: 10.7717/peerj.1902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 Michaelis M, Geiler J, Naczk P, Sithisarn P, Ogbomo H, Altenbrandt B, Leutz A, Doerr HW, Cinatl J Jr. Glycyrrhizin inhibits highly pathogenic H5N1 influenza A virus-induced pro-inflammatory cytokine and chemokine expression in human macrophages. Med Microbiol Immunol 2010;199:291-7. [PMID: 20386921 DOI: 10.1007/s00430-010-0155-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
50 Fedson DS, Opal SM. Research into transmissibility of influenza A H5N1: a practical response to the controversy. The Lancet Infectious Diseases 2012;12:364-5. [DOI: 10.1016/s1473-3099(12)70079-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Tavares LP, Teixeira MM, Garcia CC. The inflammatory response triggered by Influenza virus: a two edged sword. Inflamm Res 2017;66:283-302. [PMID: 27744631 DOI: 10.1007/s00011-016-0996-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 7.5] [Reference Citation Analysis]
52 Yamane K, Indalao IL, Chida J, Yamamoto Y, Hanawa M, Kido H. Diisopropylamine dichloroacetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza. PLoS One 2014;9:e98032. [PMID: 24865588 DOI: 10.1371/journal.pone.0098032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
53 Yang H, Zhang W, Huang C, Zhou W, Yao Y, Wang Z, Li Y, Xiao W, Wang Y. A novel systems pharmacology model for herbal medicine injection: a case using Reduning injection. BMC Complement Altern Med 2014;14:430. [PMID: 25366653 DOI: 10.1186/1472-6882-14-430] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
54 Bray M, Lawler J, Paragas J, Jahrling PB, Mollura DJ. Molecular imaging of influenza and other emerging respiratory viral infections. J Infect Dis 2011;203:1348-59. [PMID: 21422476 DOI: 10.1093/infdis/jir038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
55 Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res 2011;162:19-30. [PMID: 21963677 DOI: 10.1016/j.virusres.2011.09.022] [Cited by in Crossref: 199] [Cited by in F6Publishing: 179] [Article Influence: 18.1] [Reference Citation Analysis]
56 McCullers JA. Preventing and treating secondary bacterial infections with antiviral agents. Antivir Ther 2011;16:123-35. [PMID: 21447860 DOI: 10.3851/IMP1730] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
57 Howard WA, Peiris M, Hayden FG. Report of the 'mechanisms of lung injury and immunomodulator interventions in influenza' workshop, 21 March 2010, Ventura, California, USA. Influenza Other Respir Viruses 2011;5:453-4, e458-75. [PMID: 21848616 DOI: 10.1111/j.1750-2659.2011.00278.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
58 Hampson AW. The 'novel' influenza A(H1N1) enigma: is it a pandemic, how should we respond, what should we call it? Influenza Other Respir Viruses 2009;3:119-20. [PMID: 19627368 DOI: 10.1111/j.1750-2659.2009.00092.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
59 Richards GA, Sprung CL; European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster. Chapter 9. Educational process. Recommendations and standard operating procedures for intensive care unit and hospital preparations for an influenza epidemic or mass disaster. Intensive Care Med 2010;36 Suppl 1:S70-9. [PMID: 20213424 DOI: 10.1007/s00134-010-1768-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
60 Garcia CC, Russo RC, Guabiraba R, Fagundes CT, Polidoro RB, Tavares LP, Salgado AP, Cassali GD, Sousa LP, Machado AV, Teixeira MM. Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice. PLoS Pathog 2010;6:e1001171. [PMID: 21079759 DOI: 10.1371/journal.ppat.1001171] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
61 Moseley CE, Webster RG, Aldridge JR. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respir Viruses 2010;4:307-11. [PMID: 20716159 DOI: 10.1111/j.1750-2659.2010.00155.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
62 Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses 2013;7 Suppl 1:63-75. [PMID: 23279899 DOI: 10.1111/irv.12045] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
63 Carey MA, Bradbury JA, Rebolloso YD, Graves JP, Zeldin DC, Germolec DR. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One. 2010;5:e11610. [PMID: 20657653 DOI: 10.1371/journal.pone.0011610] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
64 Govorkova EA, McCullers JA. Therapeutics against influenza. Curr Top Microbiol Immunol 2013;370:273-300. [PMID: 22246228 DOI: 10.1007/82_2011_198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
65 Kruger PS, Thomas RM. Statins in pneumonia--magic versus science? Crit Care 2012;16:157. [PMID: 23025797 DOI: 10.1186/cc11479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Liu KC, Fang JM, Jan JT, Cheng TJ, Wang SY, Yang ST, Cheng YS, Wong CH. Enhanced anti-influenza agents conjugated with anti-inflammatory activity. J Med Chem 2012;55:8493-501. [PMID: 22963087 DOI: 10.1021/jm3009844] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
67 Wong ZX, Jones JE, Anderson GP, Gualano RC. Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. Influenza Other Respir Viruses 2011;5:343-50. [PMID: 21668689 DOI: 10.1111/j.1750-2659.2011.00235.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]